Federal Bid

Last Updated on 20 Aug 2015 at 8 AM
Solicitation
Clifton Arizona

Serogroup B Meningococcal Immunogenicity Study

Solicitation ID 2015-80812
Posted Date 21 Jul 2015 at 1 PM
Archive Date 20 Aug 2015 at 5 AM
NAICS Category
Product Service Code
Set Aside No Set-Aside Used
Contracting Office Procurement And Grants Office (Atlanta)
Agency Department Of Health And Human Services
Location Clifton Arizona United states
The Centers for Disease Control and Prevention, NCIRD/DBD/MVPDB, 1600 Clifton Rd. NE, Atlanta, GA, 30333, hereby announces its intent to issue a sole source contract in accordance with FAR 6.302-1 to Nicole E Basta, PhD Mphil, University of Minnesota to evaluate the duration of protection of newly licensed Serogroup B meningococcal vaccines to inform national policy recommendations regarding routine use of this vaccine in the US population.

The statutory authority permitting other than full and open competition is 41 U.S.C. 253(c)(1) as cited in FAR 6.302-1, "Only one responsible source and no other supplies or services will satisfy agency requirements."In 2013, Princeton University expreienced an outbreak of Serogroup B Meningococcal disease among its undergraduate students. To control the outbreak, CDC received authorization from the FDA to vaccinate university students with an investigational Serogroup B Meningococcal vaccine. Dr. Basta independently initiated a study among students to assess immunogencicty of the vaccine. Since Serogroup B vaccines were not yet recommended for general public use, Princeton University students are unique in that coverage with Serogroup B vaccination occurred in >95% of this population. The purpose of this potential contract will be to extend Dr. Basta's current study to measure how long protection lasts following vaccination. This information is urgently needed since it will inform future outbreak response and help address important policy decisions. Dr. Basta is the only source capable of performing this potential contract due to her unique access to the subjects previously enrolled in the immunogenicity study, is exclusively able to collaborate with Princeton University to implement the study, and is a technical expert in Meningococcal disease.

Responsible sources that believe they possess the expertise and capabilities identified above are encouraged to submit to the Contracting Officer within 15 days from the posting date of this notice, their written capabilities statement, proposal or quotation which shall be considered by the agency. Please forward the capability statement and/or pricing information to David Dombeck, Contract Officer, Reference 2015-80812, Centers for Disease Control, Procurement and Grants Office, ATTN: David Dombeck, MS: K-14, 2920 Brandywine Road, Atlanta, GA 30341. All vendors must be registered in the System for Award Management (SAM) prior to an award of a federal contract. The website is: www.sam.gov.

The Government will review any/all capabilities statements and pricing information submitted and determine if other qualified sources do exist that could provide this requirement. Information received in response to this announcement will be used solely for the purpose of determining whether to conduct a competitive procurement.

If no affirmative responses are received within 15 days, negotiations will be conducted with the Dr. Basta, as the only source and a contract will be issued without any additional notices being posted.

Bid Protests Not Available

Similar Past Bids

Location Unknown 22 Aug 2015 at 7 PM
Detroit Michigan 03 Mar 2021 at 5 AM
Location Unknown 17 May 2022 at 4 AM
Austin Texas 11 Jan 2021 at 5 AM
San jose California 05 Mar 2021 at 5 AM